Oruka Therapeutics GAAP EPS of -$0.55 misses by $0.01 (NASDAQ:ORKA)
Oruka Therapeutics press release (ORKA): Q2 GAAP EPS of -$0.55 misses by $0.01. As of June 30, 2026, Oruka had cash, cash equivalents and marketable securities
YayaNews contributes financial news and market context through the YayaNews editorial workflow.
Oruka Therapeutics press release (ORKA): Q2 GAAP EPS of -$0.55 misses by $0.01. As of June 30, 2026, Oruka had cash, cash equivalents and marketable securities
Oruka Therapeutics GAAP EPS of -$0.55 misses by $0.01 (NASDAQ:ORKA) | Seeking Alpha
Oruka Therapeutics
press release
(
ORKA
): Q2 GAAP EPS of -$0.55
misses by $0.01
.
As of June 30, 2026, Oruka had cash, cash equivalents, and marketable securities of $1.1 billion. The company expects these funds to be sufficient to fund operations through an anticipated BLA filing for ORKA-001 and continued development of ORKA-002.
More on Oruka Therapeutics
Oruka Therapeutics Is Priced For Perfection - It's Time To Cash Out
Oruka Therapeutics - Intriguing Long Acting Psoriasis Programs May Need Further Derisking
Seeking Alphaâs Quant Rating on Oruka Therapeutics
Historical earnings data for Oruka Therapeutics
Financial information for Oruka Therapeutics
To ensure this doesnât happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please
report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.
Search field
Entering text into the input field will update the search result below
Recommended For You
More
Trending News
See More
»
Original YayaNews editorial coverage, published for informational purposes.
This article is sourced from Seeking Alpha. It is for informational purposes only and does not constitute investment advice.
Topics & Symbols
Continue Reading
Related Reading
Solana Company Stakes 500K SOL on Tokyo Cluster, Validator Rewards Expected by Q3 2026
A Solana infrastructure firm has pledged 500,000 SOL to support its Tokyo cluster, with first validator rewards projected for Q3 2026, signaling confidence in network decentralization and Asian expansion.
Barfresh outlines $23M-$26M FY2026 revenue outlook while targeting partial commissioning of Defiance plant by end of 2026 (NASDAQ:BRFH)
Barfresh (BRFH) Q2 2026 earnings call recap: Arps-driven revenue growth, production ramp issues, and revised FY2026 guidance.
Sidus Fortis VPX Commercial Launch in 2027 Backed by $158.5M Funding
Sidus Space announces the commercial availability of its Fortis VPX edge computing module by early 2027, supported by $158.5M raised in Q2 2025. Learn about its technology advantages, market outlook, and financial health.
TOMI Reaffirms 2026 Revenue Guidance of at Least $12M, Sets $10M Funding Goal for Carbonium Core Merger
TOMI Environmental Solutions reaffirms its 2026 revenue guidance of at least $12 million and advances its merger with Carbonium Core, targeting $10 million in funding. This article analyzes the strategic implications, industry context, and potential risks.
